Oluyemi Okupe - 03 Feb 2026 Form 4 Insider Report for Hims & Hers Health, Inc. (HIMS)

Role
Chief Financial Officer
Signature
/s/ Kimberly Mather, Attorney-in-Fact for Oluyemi Okupe
Issuer symbol
HIMS
Transactions as of
03 Feb 2026
Net transactions value
-$112,745
Form type
4
Filing time
04 Feb 2026, 16:13:24 UTC
Previous filing
21 Jan 2026
Next filing
25 Feb 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Okupe Oluyemi Chief Financial Officer 2269 CHESTNUT STREET, #523, SAN FRANCISCO /s/ Kimberly Mather, Attorney-in-Fact for Oluyemi Okupe 04 Feb 2026 0001907056

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HIMS Class A Common Stock Options Exercise $26,363 +5,262 +5.7% $5.01 96,879 03 Feb 2026 Direct F1
transaction HIMS Class A Common Stock Sale $139,108 -5,262 -5.4% $26.44 91,617 03 Feb 2026 Direct F2
holding HIMS Class A Common Stock 7,853 03 Feb 2026 Held by Oluyemi Okupe Separate Property Trust dtd 9-1-2021

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HIMS Stock Option (right to buy) Options Exercise $0 -5,262 -3.5% $0.000000 144,051 03 Feb 2026 Class A Common Stock 5,262 $5.01 Direct F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The stock option exercises and sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted on May 21, 2025 by the Reporting Person.
F2 Price reported constitutes the average weighted price of shares sold. Shares were sold at varying prices in the range of $26.35-$26.56. The Reporting Person hereby undertakes, upon request of the Commission, the issuer or a security holder of the issuer, to provide full information regarding the number of shares sold at each separate price.
F3 The Reporting Person received stock options to purchase shares of Class A Common Stock. The stock options vest over a 4-year period, with 1/48 of the shares vesting when the Reporting Person completes each month of continuous service, beginning March 24, 2022.